Bioatla

Bioatla R&D per Employee

The R&D Spending per Employee of Bioatla (BCAB) as of Nov 18, 2026 is 660,196.97 USD. In the previous year, R&D Spending per Employee was 955,984.85 USD — a change of -30.94% (lower).

R&D per Employee

660,196.97USD

YoY

-30.94%

Last updated:

R&D Spending per Employee of Bioatla is 2025 660,196.97 USD. R&D Spending per Employee of Bioatla was 2024 955,984.85 USD. It decreases by -30.94% lower compared to the previous year.

The Bioatla R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
398,560.61 USD
Jan 1, 2019
392,712.12 USD
Jan 1, 2020
302,015.15 USD
Jan 1, 2021
882,939.39 USD
Jan 1, 2022
1.20 M USD
Jan 1, 2023
1.57 M USD
Jan 1, 2024
955,984.85 USD
Jan 1, 2025
660,196.97 USD
The Bioatla R&D per Employee history
YEARR&D per EmployeeYoY
660,196.97USD-30.94%
955,984.85USD-39.17%
1.57 MUSD+30.73%
1.20 MUSD+36.16%
882,939.39USD+192.35%
302,015.15USD-23.10%
392,712.12USD-1.47%
398,560.61USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioatla Stock analysis

What does Bioatla do? BioAtla develops antibody-based therapeutics for solid tumor cancer, focusing on conditionally active biologics (CAB) antibody-drug conjugates (ADCs). Its lead product BA3011 targets AXL, a protein kinase receptor, while BA3021 targets ROR2, a receptor tyrosine kinase. BA3071 is a CAB anti-CTLA-4 antibody for multiple solid tumors including renal cell carcinoma and melanoma, and BA3182 uses Dual-CAB technology for adenocarcinoma treatment. The company generates revenue through the development and commercialization of these product candidates, targeting oncology treatment markets with specific therapeutic approaches. BioAtla's product pipeline includes BA3011, BA3021, BA3071, and BA3182, each addressing distinct cancer targets. The company focuses on developing novel therapeutics rather than selling existing products, with BA3011 as its lead candidate. Revenue is expected from future partnerships, licensing agreements, or eventual product sales once clinical development progresses to later stages. The company's business model centers on advancing its pipeline through clinical trials, with potential revenue streams from biopharmaceutical partnerships and product launches. BA3071 targets multiple solid tumor indications, including NSCLC and hepatocellular carcinoma, while BA3182 is designed for advanced adenocarcinoma. BioAtla's focus on CAB technology differentiates its approach in the oncology space. Bioatla is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioatla stock

R&D Spending per Employee of Bioatla is 660,196.97 USD in 2025.

R&D Spending per Employee of Bioatla changed from 955,984.85 USD to 660,196.97 USD, representing a -30.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Bioatla since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Bioatla historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Bioatla

All Key Metrics — Bioatla